,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-05-06 22:23:00,St. Jude Medical ( STJ ) has enrolled the first patient for its MultiPoint Pacing clinical study.,0.41979727149009705,0.010210440494120121,0.5699922442436218,neutral,0.4095868170261383
1,2013-05-06 22:23:00,The study will evaluate the efficacy of the company's Quadripolar Pacing system belonging to the implantable cardioverter defibrillator (ICD) product line under the larger Cardiac Rhythm Management (CRM) division.,0.12237397581338882,0.006476010195910931,0.8711499571800232,neutral,0.11589796841144562
2,2013-05-06 22:23:00,Quadripolar Pacing is becoming the new standard of care in cardiac resynchronization therapy (CRT).,0.44576743245124817,0.010553398169577122,0.5436791777610779,neutral,0.4352140426635742
3,2013-05-06 22:23:00,MultiPoint Pacing technology delivers pacing to multiple locations in the heart rather than the traditional single pulse for each heartbeat.,0.072267085313797,0.007096145302057266,0.9206367135047913,neutral,0.06517094373703003
4,2013-05-06 22:23:00,The study will analyze the benefits of St. Jude's one-of-a-kind Quadra Assura MP CRT-D and Quartet lead in delivering improved hemodynamic support in patients receiving CRT.,0.8149860501289368,0.01305268332362175,0.1719612330198288,positive,0.8019333481788635
5,2013-05-06 22:23:00,The MultiPoint Pacing clinical study is being conducted under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA).,0.07698960602283478,0.0062605091370642185,0.916749894618988,neutral,0.070729099214077
6,2013-05-06 22:23:00,"The study will enroll more than 500 patients across 50 centers in the U.S. As per the Heart Failure Society of America, about 5 million people in the U.S are suffering from heart failure with roughly 400,000 to 700,000 new patients diagnosed annually.",0.08407116681337357,0.06170843541622162,0.8542203903198242,neutral,0.022362731397151947
7,2013-05-06 22:23:00,St. Jude Medical is the only company that offers quadripolar CRT-D technology in the U.S. and Japan and has recently launched the world's first quadripolar MultiPoint Pacing technology in Europe.,0.3909851014614105,0.00789251085370779,0.6011224389076233,neutral,0.38309258222579956
8,2013-05-06 22:23:00,This provides a competitive advantage to the company's CRT segment to gain market share in the ICD market.,0.9395739436149597,0.015275651589035988,0.045150402933359146,positive,0.9242982864379883
9,2013-05-06 22:23:00,St. Jude's core CRM division is still underperforming.,0.020944423973560333,0.9639315009117126,0.015124112367630005,negative,-0.9429870843887329
10,2013-05-06 22:23:00,Revenues from the CRM division fell 8% year over year in the first quarter of 2013.,0.01768123358488083,0.9733211398124695,0.008997714146971703,negative,-0.9556398987770081
11,2013-05-06 22:23:00,"The beleaguered ICD market, as reflected by sustained implant volume pressure and the Riata/Durata lead issue, continues to hurt CRM results.",0.02041614055633545,0.9668582081794739,0.012725592590868473,negative,-0.9464420676231384
12,2013-05-06 22:23:00,ICD sales declined 5% in the first quarter but we believe that market trends will stabilize soon.,0.042124126106500626,0.9188238382339478,0.039051953703165054,negative,-0.876699686050415
13,2013-05-06 22:23:00,"Additionally, the pacemaker business under CRM is currently losing market share due to competitive pressure.",0.017432309687137604,0.9667315483093262,0.015836164355278015,negative,-0.9492992162704468
14,2013-05-06 22:23:00,"Recently, the company received CE Mark approval for its Allure Quadra Cardiac Resynchronization Therapy Pacemaker (CRT-P).",0.8708166480064392,0.01264719944447279,0.11653611809015274,positive,0.858169436454773
15,2013-05-06 22:23:00,It is the world's first pacemaker with the quadripolar lead technology.,0.46456223726272583,0.01003660075366497,0.5254011750221252,neutral,0.4545256495475769
16,2013-05-06 22:23:00,The European launch of this product should help STJ's soft pacemaker business to regain some lost market share.,0.9445018172264099,0.021812640130519867,0.03368556872010231,positive,0.9226891994476318
17,2013-05-06 22:23:00,"St. Jude's peer Boston Scientific ( BSX ) also reported disappointing CRM sales in the first quarter of 2013, indicating sustained softness in the CRM market.",0.019286779686808586,0.9697902202606201,0.010922987014055252,negative,-0.9505034685134888
18,2013-05-06 22:23:00,St. Jude currently carries a Zacks Rank #3 (Hold).,0.03989259898662567,0.020126808434724808,0.9399806261062622,neutral,0.019765790551900864
19,2013-05-06 22:23:00,"While we remain on the sidelines regarding STJ, medical stocks such as Conceptus ( CPTS ) and Coventry Health Care ( CVH ) warrant a look.",0.04354199767112732,0.011004259809851646,0.9454537034034729,neutral,0.032537735998630524
20,2013-05-06 22:23:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
21,2013-05-06 22:23:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
